Charles River And Wheeler Bio Complete Agreement To Accelerate The Journey From Discovery And CMC Development To Manufacturing
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (CRL) and Wheeler Bio have announced a strategic agreement to provide early-stage biotech companies with a streamlined path from discovery to first-in-human clinical trials. This partnership combines Charles River's expertise in antibody discovery, safety, and analytics with Wheeler Bio's Portable CMC platform, aiming to accelerate therapeutic discovery to IND submission timelines and reduce the complexity of managing multiple vendor relationships.
February 21, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories International, Inc. (CRL) enters a strategic partnership with Wheeler Bio to offer a comprehensive solution for early-stage biotech companies, aiming to streamline the process from discovery to clinical trials.
The partnership with Wheeler Bio enhances Charles River's service offerings, potentially attracting more clients seeking streamlined development processes. This could lead to increased revenue and a positive market perception, supporting a short-term positive impact on CRL's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90